tenx_8k
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
Date of Report (Date of earliest event reported): November 18,
2020
Tenax
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-34600
|
|
26-2593535
|
|
(State
or other jurisdiction of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
ONE Copley Parkway, Suite 490
Morrisville, NC 27560
(Address
of principal executive offices) (Zip Code)
919-855-2100
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
Trading
Symbol(s)
|
Name of
each exchange on which registered
|
|
Common
Stock, $0.0001 par value per share
|
TENX
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR 240.12b-2).
Emerging growth
company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
☐
Item 7.01. Regulation FD Disclosure.
On
November 18, 2020 at 4:30 p.m. EST, Tenax Therapeutics, Inc. (the
“Company”) will present an investor R&D
presentation (the “Presentation”) to share updates
related to levosimendan and the Company’s recently completed
Phase 2 trial for the treatment of patients with pulmonary
hypertension and heart failure with preserved ejection fraction. A
copy of this Presentation is attached as Exhibit 99.1 to this
Current Report on Form 8-K.
The
information contained in Item 7.01 of this report and in Exhibit
99.1 shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
Item 9.01. Exhibits.
(d)
Exhibits.
|
Exhibit No.
|
|
Description
|
|
|
|
Tenax
Investor R&D Webinar Presentation, dated November 18,
2020
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Date: November 18, 2020
|
Tenax Therapeutics, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
By: /s/ Michael
B. Jebsen
|
|
|
|
Michael
B. Jebsen
|
|
|
|
President
and Chief Financial Officer
|
|
